Category Archives: Parkinson’s Treatment

The murmurs about President Joe Bidens health and particularly commentary about whether hes exhibiting signs of Parkinsons disease have reached a fever pitch. Continue reading →

Berlin, Germany, and Research Triangle Park, N.C., USA, July 11, 2024 Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track Designation for AB-1005, which is being developed for moderate Parkinsons disease. Continue reading →

An expert on Parkinsons disease from Walter Reed National Military Medical Center visited the White House eight times in eight months from last summer through this spring, including at least once for a meeting with President Bidens physician, according to official visitor logs. Continue reading →

Washington, D.C. Continue reading →

Episode 119 of the NeurologyLiveMind Moments podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service. Continue reading →

The progressive neurodegenerative condition affects around 153,000 people in the UK Mission Therapeutics has been awarded $5.2m in funding from Parkinsons UKs Virtual Biotech programme and the Michael J. Fox Foundation to advance a potential treatment for early-stage Parkinsons disease (PD) Continue reading →

Six months of once-daily buntanetap halted cognitive decline among people in the early stages of Parkinsons disease, and improved cognition in those with mild dementia. Thats according to new data from a Phase 3 trial (NCT05357989), which showed that the therapy candidate, developed by Annovis Bio, also improved motor function in patients with a diagnosis more than three years prior, as well as in those with postural instability and gait difficulties. We are very pleased to see improvements in many of our patients over such a short course of treatment, Maria Maccecchini, PhD, founder, president, and CEO of Annovis Bio, said in a company press release. Continue reading →

West Virginia has the third-highest prevalence rate of Parkinsons in the country with about 7,000 people living with the disease, according to the Economic Burden of Parkinsons Disease study published in 2019. Continue reading →

BEACHWOOD, Ohio Just past the shadows of Cleveland Browns Stadium, Beachwood's InMotion offers a sense of community for people living with Parkinson's disease. "There's a misconception about Parkinson's out there," said Cathe Schwartz, CEO of InMotion. "I think Parkinson's still has a stigma." But Schwartz said the reality is people can live productive, positive lives with the nervous system disease. Continue reading →

The first three Parkinsons disease patients who received a low dose of TED-A9, an investigational stem cell-based therapy being developed by S.Biomedics, saw reduced motor symptoms after a year without any reported side effects. The results come from a small Phase 1/2 clinical study (NCT05887466) where 12 adults with a diagnosis of Parkinsons for five or more years received a single transplant of TED-A9, at either a low or high dose, directly into the brain. The clinical results demonstrated very promising efficacy, Dong-Wook Kim, MD, PhD, a professor at Yonsei University College of Medicine in Seoul, South Korea, and chief technology officer at S.Biomedics, said in a company press release. Continue reading →